Scarica l'app Stockscreener
9.64
5.02%
-0.51
Dopo l'orario di chiusura:
9.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Should I add Relay Therapeutics Inc stock to my portfolio2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6%Should You Buy? - MarketBeat
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib - Sahm
Relay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Decrease in Short Interest - MarketBeat
Citizens reiterates Relay Therapeutics stock rating ahead of data By Investing.com - Investing.com Canada
Aug Levels: Is Relay Therapeutics Inc stock showing strong momentum2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Relay Therapeutics’ Promising Path with FDA Approvals and Revenue Growth - timothysykes.com
Bank Watch: What is the earnings history of Relay Therapeutics IncWeekly Profit Summary & Growth Focused Stock Pick Reports - baoquankhu1.vn
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March - Sahm
Relay Therapeutics Surges After Breakthrough Designation for Breast Cancer Treatment - StocksToTrade
Relay Therapeutics’ Q4 Financial Performance Surges Amid Breakthrough Recognition - timothysykes.com
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest - Yahoo Finance
Relay Therapeutics stock hits 52-week high at 9.64 USD By Investing.com - Investing.com Canada
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million - AOL.com
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 61.57% Potential Upside in Precision Medicine - DirectorsTalk Interviews
RLAY: Wells Fargo Raises Price Target to $15, Maintains Overweig - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $15.00 - MarketBeat
RLAY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Relay Therapeutics Shares Jump 19% On Earnings And Pipeline Progress - Nasdaq
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week High on Strong Earnings - MarketBeat
Relay Therapeutics stock hits 52-week high at 9.64 USD - Investing.com Nigeria
Decoding Relay Therapeutics Inc (RLAY): A Strategic SWOT Insight - GuruFocus
Relay Therapeutics (NASDAQ:RLAY) Announces Quarterly Earnings Results - MarketBeat
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Relay Therapeutics (RLAY) Surpasses Q4 Revenue Estimates, Eyes C - GuruFocus
Relay Therapeutics Q4 Loss Narrows, Revenue Rises; Cash Runway Into 2029 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics Posts Q4 Loss Per Share $0.32, vs. FactSet Est of $0.40 Loss - marketscreener.com
Relay Therapeutics beats Q4 revenue expectations - TradingView
Relay Therapeutics Q4 Earnings Assessment - Benzinga
Relay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q4 Revenue $7.0M, vs. FactSet Est of $5.0M - marketscreener.com
Relay Therapeutics (NASDAQ: RLAY) narrows 2025 loss and sets major 2026 zovegalisib data milestones - Stock Titan
Cancer drug developer lines up 2026 trial milestones backed by $555M cash - Stock Titan
Relay Therapeutics earnings in spotlight after FDA breakthrough By Investing.com - Investing.com UK
Relay Therapeutics earnings in spotlight after FDA breakthrough - Investing.com
Private Capital Advisors Inc. Cuts Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics Earnings Preview - Benzinga
Relay Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Investors get two chances to hear Relay Therapeutics in March - Stock Titan
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Could a 65.91% Upside Potential Spark Investor Interest? - DirectorsTalk Interviews
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - The Manila Times
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Quiver Quantitative
Precision medicine firm Relay Therapeutics sets Feb. 26 results release - Stock Titan
Investment Report: Is HEES stock suitable for long term investingPortfolio Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
Relay earnings in focus as FDA breakthrough fuels optimism By Investing.com - Investing.com Australia
Relay Therapeutics (RLAY) to Release Quarterly Earnings on Wednesday - MarketBeat
Casdin funds hold 13M Relay Therapeutics (RLAY) shares in passive stake - Stock Titan
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Trend Review: Will Relay Therapeutics Inc. benefit from government policyWeekly Investment Recap & AI Powered Market Entry Strategies - mfd.ru
Can Relay Therapeutics Inc. expand its profit marginsPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru
Relay Therapeutics, Inc. (RLAY) Stock Analysis: 71% Upside Potential as Analysts Show Strong Buy Confidence - DirectorsTalk Interviews
Relay Therapeutics shares climb after Oppenheimer lifts rating - MSN
Can Relay Therapeutics Inc. sustain its profitability2025 Bull vs Bear & Low Risk High Reward Trade Ideas - mfd.ru
Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com - Investing.com Australia
Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month HighTime to Buy? - MarketBeat
Relay Therapeutics stock hits 52-week high at $9.16 - Investing.com
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):